PCN101 Real-World Economic Outcomes of First-Line (1L) Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Abstract
Authors
S. Challagulla P. Lee K. Kistler L. Douyon D. Lai R. Iyengar